IO Biotech Announces Publication of Preclinical Data Investigating Immune-Modulatory Effects of IO112, an Arginase 1-Targeting Therapeutic Cancer…

Posted: February 5, 2025 at 2:42 am

– Submission of Investigational New Drug Application (IND) to US FDA expected in 2025 –

Original post:
IO Biotech Announces Publication of Preclinical Data Investigating Immune-Modulatory Effects of IO112, an Arginase 1-Targeting Therapeutic Cancer...

Related Posts